File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: HOXC10 upregulation confers resistance to chemoradiotherapy in ESCC tumor cells and predicts poor prognosis

TitleHOXC10 upregulation confers resistance to chemoradiotherapy in ESCC tumor cells and predicts poor prognosis
Authors
Keywordsadjuvant radiotherapy
animal experiment
animal model
animal tissue
cancer adjuvant therapy
Issue Date2020
PublisherSpringer Nature [academic journals on nature.com]: Hybrid Journal. The Journal's web site is located at http://www.nature.com/onc
Citation
Oncogene, 2020, v. 39 n. 32, p. 5441-5454 How to Cite?
AbstractEsophageal squamous cell carcinoma (ESCC) is a malignant disease and is a common cause of death in China. By performing an integrative study investigating public databases and clinical samples collected by our group, we found that HOXC10 (homeobox C10) is upregulated in ESCC tumor tissues compared with nontumor tissues and that the upregulation of HOXC10 is correlated with the poor prognosis of patients with ESCC. The enforced expression of HOXC10 promoted ESCC cell proliferation in vitro and in vivo. Our study revealed that HOXC10 could bind the promoter region of human Erb-b2 receptor tyrosine kinase 3 (ERBB3/HER3) and activate the PI3K/AKT pathway. In addition, by immunoprecipitation and mass spectrometry analysis, we found that HOXC10 could bind X-ray repair cross complementing 6 (Ku70) and accelerate the DNA repair mechanism via the nonhomologous end-joining (NHEJ) pathway. We further evaluated HOXC10 expression in ESCC patients receiving adjuvant radiotherapy or platinum-based chemotherapy. The results demonstrate that HOXC10 upregulation predicts the poor prognosis of ESCC patients receiving adjuvant radiotherapy or chemotherapy. Our study reveals that HOXC10 upregulation reflects the poor prognosis of ESCC patients and directs the selection of postoperative therapy regimens.
Persistent Identifierhttp://hdl.handle.net/10722/287271
ISSN
2019 Impact Factor: 7.971
2015 SCImago Journal Rankings: 4.047

 

DC FieldValueLanguage
dc.contributor.authorSuo, D-
dc.contributor.authorWang, Z-
dc.contributor.authorLi, L-
dc.contributor.authorCHEN, Q-
dc.contributor.authorZeng, T-
dc.contributor.authorLiu, R-
dc.contributor.authorYun, J-
dc.contributor.authorGuan, XY-
dc.contributor.authorLi, Y-
dc.date.accessioned2020-09-22T02:58:26Z-
dc.date.available2020-09-22T02:58:26Z-
dc.date.issued2020-
dc.identifier.citationOncogene, 2020, v. 39 n. 32, p. 5441-5454-
dc.identifier.issn0950-9232-
dc.identifier.urihttp://hdl.handle.net/10722/287271-
dc.description.abstractEsophageal squamous cell carcinoma (ESCC) is a malignant disease and is a common cause of death in China. By performing an integrative study investigating public databases and clinical samples collected by our group, we found that HOXC10 (homeobox C10) is upregulated in ESCC tumor tissues compared with nontumor tissues and that the upregulation of HOXC10 is correlated with the poor prognosis of patients with ESCC. The enforced expression of HOXC10 promoted ESCC cell proliferation in vitro and in vivo. Our study revealed that HOXC10 could bind the promoter region of human Erb-b2 receptor tyrosine kinase 3 (ERBB3/HER3) and activate the PI3K/AKT pathway. In addition, by immunoprecipitation and mass spectrometry analysis, we found that HOXC10 could bind X-ray repair cross complementing 6 (Ku70) and accelerate the DNA repair mechanism via the nonhomologous end-joining (NHEJ) pathway. We further evaluated HOXC10 expression in ESCC patients receiving adjuvant radiotherapy or platinum-based chemotherapy. The results demonstrate that HOXC10 upregulation predicts the poor prognosis of ESCC patients receiving adjuvant radiotherapy or chemotherapy. Our study reveals that HOXC10 upregulation reflects the poor prognosis of ESCC patients and directs the selection of postoperative therapy regimens.-
dc.languageeng-
dc.publisherSpringer Nature [academic journals on nature.com]: Hybrid Journal. The Journal's web site is located at http://www.nature.com/onc-
dc.relation.ispartofOncogene-
dc.subjectadjuvant radiotherapy-
dc.subjectanimal experiment-
dc.subjectanimal model-
dc.subjectanimal tissue-
dc.subjectcancer adjuvant therapy-
dc.titleHOXC10 upregulation confers resistance to chemoradiotherapy in ESCC tumor cells and predicts poor prognosis-
dc.typeArticle-
dc.identifier.emailLi, L: lilei728@hku.hk-
dc.identifier.emailGuan, XY: xyguan@hku.hk-
dc.identifier.authorityGuan, XY=rp00454-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1038/s41388-020-1375-4-
dc.identifier.pmid32587398-
dc.identifier.scopuseid_2-s2.0-85087059649-
dc.identifier.hkuros314316-
dc.identifier.volume39-
dc.identifier.issue32-
dc.identifier.spage5441-
dc.identifier.epage5454-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats